Abivax SA - American Depositary Shares (ABVX)
Frequently Asked Questions About Abivax SA - American Depositary Shares (ABVX)
Has Abivax SA completed any clinical trials?
Yes, Abivax SA has successfully completed several clinical trials for its lead candidate, ABX464. These trials have demonstrated positive results regarding the safety and efficacy of the drug in treating ulcerative colitis, and the company continues to advance its clinical program with additional studies.
How can investors learn more about Abivax SA?
Investors interested in learning more about Abivax SA can visit its official website, where they can find information about the company's pipeline, news releases, financial reports, and upcoming events. Additionally, investors can follow the company's updates on financial news platforms and through investor relations communications.
Is Abivax SA publicly traded?
Yes, Abivax SA is publicly traded and listed on Nasdaq under the ticker symbol ABVX. The company went public to raise funds for its clinical development and to provide investors with an opportunity to participate in its growth and the potential success of its therapies.
What are American Depositary Shares (ADS) in the context of Abivax SA?
American Depositary Shares (ADS) are a way for U.S. investors to invest in foreign companies like Abivax SA. Each ADS represents a specified number of the company’s ordinary shares. This allows investors to trade shares of international companies on U.S. stock exchanges such as Nasdaq, where Abivax is listed under the ticker symbol ABVX.
What challenges do inflammatory diseases present?
Inflammatory diseases present significant challenges to patients and healthcare systems, including fluctuating symptoms, chronic pain, and potential complications. Many existing treatments are inadequate, leading to a demand for novel therapies that can effectively manage these conditions and improve patient outcomes.
What does Abivax SA do?
Abivax SA is a clinical-stage biotechnology company focused on the development of innovative therapies for inflammatory and viral diseases. The company aims to address unmet medical needs through its unique drug candidates leveraging proprietary technologies. Its most notable asset is ABX464, which is being investigated as a treatment for conditions such as ulcerative colitis and HIV.
What funding has Abivax received?
Abivax has successfully raised funds through various financing rounds, including initial public offerings and private placements. This funding is crucial for supporting the company's ongoing clinical trials and research initiatives, allowing it to advance its drug candidates towards commercialization.
What is ABX464?
ABX464 is Abivax's leading drug candidate, designed to treat inflammatory diseases such as ulcerative colitis and Crohn's disease, along with a potential application in HIV treatment. This small molecule acts on the immune system and has shown promise in clinical trials, demonstrating an ability to restore the normal function of the immune response.
What is the company's approach to inflammatory diseases?
Abivax's approach to inflammatory diseases involves targeting the underlying mechanisms of these conditions to provide effective and lasting relief for patients. The company’s flagship drug candidate, ABX464, is designed to modulate the immune response and promote healing, showcasing a novel mechanism of action compared to existing treatments.
What is the current status of ABX464?
As of the latest update, ABX464 is undergoing Phase 2 clinical trials for ulcerative colitis, with promising preliminary results demonstrating its safety and efficacy. The company is focusing on advancing this candidate through further clinical development to potentially bring it to market.
What is the goal of Abivax’s research and development?
The goal of Abivax’s research and development is to discover and develop novel therapeutic solutions that address significant unmet medical needs in inflammatory and viral diseases. The company is committed to leveraging its unique drug candidates to improve patient outcomes and enhance healthcare.
What is the potential market for Abivax's treatments?
The potential market for Abivax's treatments, particularly for its lead candidate ABX464, is substantial given the high prevalence of inflammatory diseases such as ulcerative colitis and Crohn's disease, as well as the ongoing need for innovative HIV therapies. The growing demand for effective treatments in these areas positions Abivax to capture a significant share of the market.
What is the significance of the company's research?
The significance of Abivax’s research lies in its potential to transform the treatment landscape for patients suffering from chronic inflammatory and viral diseases. By developing therapies that target disease mechanisms rather than just symptoms, Abivax strives to offer more effective and sustainable treatment options that can improve patients’ lives.
What is the vision of Abivax SA?
Abivax’s vision is to become a leader in the biotechnology field by providing innovative treatments that significantly improve the quality of life for patients with chronic diseases. The company is committed to scientific excellence and aims to leverage its proprietary technologies to bring new therapies to market.
What partnerships does Abivax have?
Abivax has established strategic partnerships with various academic institutions and biotech companies to further its research and development efforts. These collaborations enable the sharing of knowledge, resources, and technologies to enhance the development of its drug candidates and accelerate innovation.
What types of diseases does Abivax target?
Abivax primarily targets inflammatory diseases such as ulcerative colitis and Crohn's disease, as well as viral diseases like HIV. The company aims to provide innovative treatment options for these challenging conditions, which often have limited current therapeutic alternatives.
When was Abivax SA founded?
Abivax SA was founded in 2013. Since its inception, the company has focused on developing advanced treatments based on its proprietary technologies, with the goal of improving the quality of life for patients suffering from chronic diseases.
Where is Abivax SA headquartered?
Abivax SA is headquartered in Paris, France. The company's strategic location in one of Europe's leading biotech hubs allows it to collaborate with various research institutions and biotech companies, facilitating innovation in drug development.
Who are the key players in Abivax's leadership team?
Abivax’s leadership team comprises experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and research. The team is dedicated to advancing the company’s mission of developing innovative therapies and is committed to driving the company's growth and success.
What is the current price of Abivax SA - American Depositary Shares?
The current price of Abivax SA - American Depositary Shares is 89.33
When was Abivax SA - American Depositary Shares last traded?
The last trade of Abivax SA - American Depositary Shares was at 11:43 am EDT on September 9th, 2025